Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: Moclobemide and selegiline

Clinical Neuropharmacology

Volumn 19, Issue 5, 1996, Pages 399-414

  Dingemanse, Jasper ^a   Kneer, Johannes ^a   Wallnöfer, Andreas ^a   Kettler, Rolf ^b   Zürcher, Gerhard ^b   Koulu, Markku ^c   Korn, Adrienne ^d  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Preclinical Research   (Switzerland)

^c UNIVERSITY OF TURKU   (Finland)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Catecho lamines; Interactions; Moclobemide; Monoamine oxidase inhibitors; Pharmacodynamics; Pharmacokinetics; Selegiline; Serotonin

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; DOPAMINE; DRUG METABOLITE; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PLACEBO; SELEGILINE; SEROTONIN; TYRAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG METABOLISM; DRUG MIXTURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPHARMACOLOGY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029790182     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619050-00003     Document Type: Article

References (62)

1. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry 1989;155:38-45.
2. Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol 1991;11:55-9.
3. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-97.
4. Fuller RW. Selectivity among monoamine oxidase inhibitors and its possible importance for development of antidepressant drugs. Prog Neuropsychopharmacol Biol Psychiatry 1978;2:303-11.
5. Yang HY, Neff NH. The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 1974;189:733-40.
6. Suzuki O, Katsumata Y, Masukazu O. Substrate specificity of type A and B monoamine oxidase. In: Kamijo K, Usdin E, Nagatsu T, eds. Monoamine oxidase: basic and clinical frontiers. Amsterdam: Excerpta Medica, 1982:74-86.
7. Cummings JL. Depression and Parkinson's disease. Am J Psychiatry 1992;149:443-54.
8. Kistemaker H, Schalekamp T, Porsius AJ, de Gier JJ. The use of neuroleptic and antidepressant agents in elderly patients with Parkinson's disease. Pharmacy World Sci 1995;17:A6.
9. Pare CMB, Mousawi MA, Sandler M, Glover V. Attempts to attenuate the "cheese effect." J Affect Disord 1985;9:137-41.
10. Koller WC, Giron LT. Selegiline HCl: selective MAO-type B inhibitor. Neurology 1990;40:58-60.
11. The Parkinson Study Group. The effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-71.
12. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
13. Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992;43:561-96.
14. Freeman H. Moclobemide. Lancet 1993;342:1528-32.
15. Priest RG, Schmid-Burgk W. Moclobemide in the treatment of depression. Rev Contemp Pharmacother 1994;5:35-43.
16. Korn A, Da Prada M, Raffesberg W, et al. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 1988;11:17-23.
17. Stefanis CN, Alevizos B, Markianos M, Hatzimanolis J. Effect of moclobemide on clinical and neurochemical variables in depressed patients. Preliminary findings. J Neural Transm 1988;26:87-95.
18. Koulu M, Scheinin M, Kaarttinen A, et al. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989;27:243-55.
19. Berlin I, Zimmer R, Thiede HM, et al. Comparison of the monoamine oxidase inhibiting properties of the two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol 1990;30:805-16.
20. Markianos M, Alevizos B, Hatzimanolis J, Stefanis C. Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients. Psychiatry Res 1994;52:259-64.
21. Bondiolotti GP, Galva MD, Villa F, et al. Effects of moclobemide treatment on plasma L-dopa and catecholamine metabolites in healthy volunteers. Experientia 1992;48:A7.
22. Thornton C, Dore CJ, Elsworth JD, Herbert M, Stern GM. The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacology 1980;70:163-6.
23. Korn A, Wagner B, Moritz E, Dingemanse J. Tyramine pressor sensitivity in healthy volunteers during combined treatment with moclobemide and selegiline. Eur J Clin Pharmacol 1996;49:273-8.
24. Bench CJ, Price GW, Lammertsma AA, et al. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 1991;40:169-73.
25. Holford NHG, Guentert TW, Dingemanse J, Kettler R. Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B. Br J Clin Pharmacol 1994;37:553-7.
26. Jauch R, Griesser E, Oesterhelt G, et al. Biotransformation of moclobemide in humans. Acta Psychiatr Scand 1990;360:87-9.
27. Geschke R, Koerner J, Eggers H. Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by HPLC. J Chromatogr 1987;420:111-20.
28. Eisenhofer G, Goldstein DS, Stull R, et al. Simultaneous liquid chromatographic determination of 3, 4-dihydroxyphenylglycol, catecholamines and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 1986;32:2030-3.
29. Minegishi A, Ishizaki T. Rapid and simple method for the simultaneous determination of 3,4-dihydroxyphenylacetic acid, 5-HIAA and 4-hydroxyphenylacetic acid in human plasma, by HPLC with electrochemical detection. J Chromatogr 1984;308:55-63.
30. 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sci 1991;49:75-84.
31. Wurtmann RJ, Axelrod J. A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharmacol 1963;12:1439-41.
32. Lowry OH, Rosebrough HJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
33. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York; Marcel Dekker, 1982.
34. Sieradzan K, Channon S, Stern GM, Lees AJ, Youdim M. The therapeutic potential of moclobemide, a reversible selective monoamineoxidase A inhibitor in Parkinson's disease. New Trends Clin Neuropharmacol 1994;8:325.
35. Ruggieri S, Stocchi F, Bramante L. MAO-A inhibitor (moclobemide) has a symptomatic effect in Parkinson's disease. Mov Disord 1994;9:S72.
36. Baldwin D, Fineberg N, Montgomery S. Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991;6:51-8.
37. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiat 1995;152:122-5.
38. Guentert TW, Mayersohn M. Clinical-pharmacokinetic profile of moclobemide and its comparison with other MAO-inhibitors. Rev Contemp Pharmacother 1994;5:19-34.
39. Michaelis K, Waitzinger J, Agvaz U, Salama Z, Plettenberg H, Jaeger H. Pharmacokinetics of l-deprenyl and N-desmethyldeprenyl in blood versus plasma after single dose oral administration of 10 mg of selegiline (Abstract). Pharmacol Res 1993;10:5331.
40. Heinonen EH, Anttila MI, Lammintausta RAS. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 1994;56:742-9.
41. Heinonen EH, Anttila MI, Lammintausta RAS. Pharmacokinetics and clinical pharmacology of selegiline. In: Szelenyi I, ed. Inhibitors of monoamine oxidase B. Basel: Birkhäuser, 1992:201-13.
42. Amrein R, Güntert TW, Dingemanse J, Lorscheid T, Stabl M, Schmid-Burgk W. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology 1992;106:S24-31.
43. Dingemanse J, Korn A, Pfefen J-P, Guentert TW. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations. Psychopharmacology 1992;106:S46-8.
44. Brown MJ, Marks NJ. Plasma DHPG concentration: a simple, sensitive and specific index of MAO-A activity in man. In: Tipton RF, Dostert P, Strolin Benedetti M, eds. Monoamine oxidase and disease. London: Academic Press, 1984:559-60.
45. Sandler M. Deprenyl, monoamine oxidase inhibitor and the 'cheese effect': some outstanding problems. In: Youdim MBH, Paykel ES, eds. Monoamine oxidase inhibitors - the state of the art, Chichester: John Wiley, 1981:207-12.
46. Sunderland T, Tariot P, Cohen RM, et al. Dose-dependent effects of deprenyl on CSF monoamine metabolites in subjects with Alzheimer's disease. Psychopharmacology 1987;91:293-6.
47. Schulz R, Antonin K-H, Hoffmann E, et al. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 1989;46:528-36.
48. Heinonen EH, Savijärvi M, Kotila M, Hajba A, Scheinin M. Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. J Neural Transm 1993;5:193-202.
49. Riederer P, Youdim MBH. Brain monoamine oxidase activity and monoamine metabolism in Parkinson patients treated with (-)deprenyl. J Neurochem 1986;46:1349-56.
50. Knoll J, Miklya I. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch Int Pharmacodyn 1994;328:1-15.
51. Tipton KF. What is it that 1-deprenyl (selegiline) might do? Clin Pharmacol Ther 1994;56:781-96.
52. Chrisp P, Mammen GJ, Sorkin EM. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in parkinson's disease. Drugs Aging 1991;1:228-48.
53. Glover V, Sandler M, Owern F, Riley GJ. Dopamine is a monoamine oxidase substrate in man. Nature 1977;265:80-1.
54. Celada P, Pérez J, Alvarez E, Artigas F. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in subjects with major depression: relationship to clinical improvement. J Clin Psychopharmacol 1992;12:309-15.
55. Celada P, Artigas F. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues. J Neurochem 1993;61:2191-8.
56. Davis BA, Kennedy SH, Durden DA, D'Souza J, Goldbloom DS, Boulton AA. The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:747-63.
57. Gleiter CH, Nilsson E, Mühlbauer B, Antonin KH, Bieck PR. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity. J Neural Transm 1992;89:129-33.
58. Da Prada M, Kettler R, Keller H, Bonetti EP. Moclobemide, a new antidepressant inhibiting platelet monoamine oxidase type-B (P/MAO-B) activity in man. Acta Pharmacol Toxicol 1986;59:108.
59. Da Prada M, Cesura AM, Launay JM, Richards JG. Platelets as a model for neurones? Experientia 1988;44:115-26.
60. Stahl SM. Platelets as pharmacological models for the receptors and biochemistry of monoaminergic neurons. In: Longenecker GL, ed. The platelets: physiology and pharmacology. Orlando: Academic Press, 1985:307-40.
61. Kremer HPH, Goekoop JG, van Kempen GMJ. Clinical use of the determination of serotonin in whole blood. J Clin Psychopharmacol 1990;10:83-7.
62. Sunderland T, Müller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 1985;86:432-7.